Table 1.
(A) Spinal cord lesion monkeys. (B) Motor cortex lesion monkeys.
| Control-antibody treated monkeys |
Anti-Nogo-A antibody treated monkeys* |
|||||
|---|---|---|---|---|---|---|
| Mk-S-C-HA | Mk-S-C-ST | Mk-S-C-BE | Mk-S-A-FR | Mk-S-A-MO | Mk-S-A-CO | |
| Hemi-section extent (%) | 90 | 63 | 75 | 56 | 80 | 85 |
| Complete transection of the dorsolateral funiculus | Yes | Yes | Yes | Yes | Yes | Yes |
| Extent of dorsal column lesion (%) | 72 | 47 | 31 | 2 | 74 | 44 |
| Extent of CS and RS territory lesion (%) | 100 | 87 | 93 | 73 | 100 | 100 |
| Extent of ventral lesion (%) | 60 | 19 | 38 | 0 | 5 | 100 |
| Volume of the lesion (in mm3) | 2.862 | 3.781 | 2.912 | 2.076 | 4.576 | 4.577 |
| Functional recovery for vertical slots (%) | 59 | 42 | 76 | 56 | 96 | 100 |
| Functional recovery for horizontal slots (%) | 41 | 0 | 79 | 52 | 71 | 100 |
| Total functional recovery (vert. + horiz. slots) (%) | 53 | 22 | 78 | 57 | 96 | 100 |
|
Untreated |
Treated with anti-Nogo-A antibody* |
|||||
| Mk-C-C-GE | Mk-C-C-RO | Mk-C-C-BI | Mk-C-A-VA | Mk-C-A-SL | Mk-C-A-MO | |
| Surface of hand area on ICMS maps (mm2) | 25 | 56 | 55 | 40 | 45 | 34 |
| Lesioned hemisphere (ipsilesional hemisphere) | Left | Left | Left | Left | Left | Left |
| Total volume of lesion (mm3) gray matter (motor cortex + post-central gyrus) | 48.7 | 14 | 20.13 | 20 | 78.2 | 41.8 |
| Volume of lesion in post-central gyrus (mm3) | 7.6 | 0 | 0 | 5.8 | 1.8 | 0 |
| Volume of lesion in sub-cortical white matter (mm3) | 0 | 0 | 0 | 0 | 130.6 | 0 |
| Normalized value of lesion size with respect to surface of hand area on ICMS maps (mm3/mm2) | 1.95 | 0.25 | 0.37 | 0.5 | 1.74 | 1.23 |
| Functional recovery for vertical slots (%) | 57 | 100 | 94 | 87 | 77 | 84 |
| Functional recovery for horizontal slots (%) | 11 | 90 | 36 | 91 | 77 | 60 |
| Total functional recovery (vertical + horizontal) (%) | 38 | 98 | 74 | 87 | 73 | 76 |
Characteristics of lesions of the 12 monkeys involved in the movement pattern analysis, as well as functional recovery data derived from the modified Brinkman board task. Data taken from previous publications: (11–13, 21).
*The anti-Nogo-A antibody used is the mAb hNogo-A (human Nogo-A sequence) in the six monkeys, except in Mk-S-A-FR in which the mouse antibody mAb 11C7 was used [see (18) for characterization of the antibodies]. The monkeys Mk-S-C-ST and Mk-S-A-FR are Macaca mulatta whereas the other 10 monkeys are Macaca fascicularis.